Ben Scruggs

Ben Scruggs is an accomplished leader in the biotechnology sector, currently serving as Chairman and CEO of Altis Biosystems since February 2023. Scruggs also holds board membership roles at VERALOX Therapeutics and IMMvention Therapeutix, Inc., and has been a principal at Hatteras Venture Partners since July 2016, where prior positions included associate and analyst. Notable prior experience includes a senior director role at Tune Therapeutics and a postdoctoral fellowship at the National Institute of Environmental Health Sciences, where significant contributions to understanding non-coding RNA and chromatin structure were made. Educational qualifications include a Ph.D. in Molecular Cell Biology from Washington University School of Medicine and a B.E. in Biomedical Engineering from Vanderbilt University, supplemented by a business credential from Harvard Business School.